Definition
Post-treatment controllers (PTC) are HIV-infected patients able to maintain a durable control of viremia at undetectable levels after interruption of antiretroviral treatment. Differently from natural HIV “elite” controllers (HIC), post-treatment controllers require therapeutic intervention to first reach undetectable viral loads. Post-treatment controllers still carry infected cells and, thus, are not cured but considered to be in sustained remission of HIV infection. These patients have also been termed “secondary controllers.”
Introduction
The introduction of combination antiretroviral treatment (cART) as the standard of care for HIV-infected individuals changed the face of the AIDS epidemics. cART has drastically reduced mortality and morbidities of HIV-infected patients (Boyd 2009) and has also proven its value as a prevention tool by decreasing the risk of transmission (Cohen et al. 2011). A few years after cART was implemented, it was hypothesized that the perfectly...
This is a preview of subscription content, log in via an institution to check access.
References
Ananworanich J, Vandergeeten C, Chomchey N, et al. Early ART intervention restricts the seeding of the HIV reservoir in long-lived central memory CD4 T cells. In: 20th conference on retroviruses and opportunistic infections, Atlanta, 3–6 Mar 2013. Abstract 47.
Ananworanich J, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS. 2014;28(7):1015–20.
Boufassa F, et al. Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. PLoS One. 2014;9(1):e85516.
Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS. 2009;4(3):194–9.
Buzon MJ, et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol. 2014;88(17):10056–65.
Cohen MS, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012;37(3):377–88.
Fiebig EW, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17(13):1871–9.
Goujard C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther. 2012;17(6):1001–9.
Hocqueloux L, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS. 2010;24(10):1598–601.
Hocqueloux L, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother. 2013;68(5):1169–78.
Hutter G, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692–8.
Lodi S, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med. 2012;172(16):1252–5.
Luzuriaga K, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J Infect Dis. 2014. doi:10.1093/infdis/jiu297.
O’Brien M, Markowitz M. Should we treat acute HIV infection? Curr HIV/AIDS Rep. 2012;9(2):101–10.
Paton NI. Treatment interruption strategies: how great are the risks? Curr Opin Infect Dis. 2008;21(1):25–30.
Persaud D, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369(19):1828–35.
Piketty C, et al. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol. 2010;82(11):1819–28.
Rosenberg ES, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407(6803):523–6.
Saez-Cirion A, Pancino G. HIV controllers: a genetically determined or inducible phenotype? Immunol Rev. 2013;254(1):281–94.
Saez-Cirion A, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9(3):e1003211.
Salgado M, et al. Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. Retrovirology. 2011;8:97.
Steingrover R, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS. 2008;22(13):1583–8.
Van Gulck E, et al. Immune and viral correlates of “secondary viral control” after treatment interruption in chronically HIV-1 infected patients. PLoS One. 2012;7(5):e37792.
Whitney JB, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512(7512):74–7.
Yukl SA, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 2013;9(5):e1003347.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this entry
Cite this entry
Sáez-Cirión, A., Hocqueloux, L., Rouzioux, C. (2014). Post-treatment Controllers. In: Hope, T., Stevenson, M., Richman, D. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9610-6_201-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9610-6_201-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-9610-6
eBook Packages: Springer Reference MedicineReference Module Medicine